GSA Capital Partners’s Roivant Sciences ROIV Stock Holding History

GSA Capital Partners’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-18,068	Closed	-$392K	–	2102
2025 Q4	$392K	Buy	+18,068	New	+$356K	0.03%	978
2025 Q2	–	Sell	-11,644	Closed	-$117K	–	2092
2025 Q1	$117K	Buy	+11,644	New	+$126K	0.01%	1478
2024 Q4	–	Sell	-32,733	Closed	-$378K	–	1968
2024 Q3	$378K	Sell	32,733 -2,180	-6%	-$24.8K	0.03%	1106
2024 Q2	$369K	Sell	34,913 -15,076	-30%	-$165K	0.03%	1155
2024 Q1	$527K	Buy	+49,989	New	+$539K	0.04%	851
2023 Q3	–	Sell	-48,215	Closed	-$486K	–	1840
2023 Q2	$486K	Sell	48,215 -438	-0.9%	-$3.92K	0.05%	760
2023 Q1	$359K	Buy	48,653 +18,824	+63%	+$155K	0.04%	917
2022 Q4	$238K	Buy	+29,829	New	+$166K	0.03%	1079

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

GSA Capital Partners's ROIV Position: Q1 2026 in Review

GSA Capital Partners sold out of Roivant Sciences (ROIV) in Q1 2026, closing a stake of 18,068 shares — an estimated $392K sold.

GSA Capital Partners first reported a position in ROIV in Q4 2022 and held it in 8 quarters. The position peaked at $527K in Q1 2024. 444 funds tracked by Wall St. Rank hold ROIV as of Q1 2026.

GSA Capital Partners reported no remaining Roivant Sciences position as of Q1 2026 after selling out during the quarter.
GSA Capital Partners sold 18,068 Roivant Sciences shares in Q1 2026, an estimated $392K.
GSA Capital Partners first reported a position in Roivant Sciences in Q4 2022 and held it in 8 quarters.
GSA Capital Partners's Roivant Sciences position peaked at $527K in Q1 2024.
444 funds tracked by Wall St. Rank held Roivant Sciences as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.